Endovastec(SH:688016) Sou Hu Cai Jing·2025-08-28 00:31Core Viewpoint - The stock of Xinmai Medical (688016) has experienced a decline of 5.22% as of August 27, 2025, closing at 112.1 yuan, with significant net outflows from major funds and a mixed performance from retail investors [1][2]. Financial Performance - Xinmai Medical reported a main revenue of 714 million yuan for the first half of 2025, a year-on-year decrease of 9.24% - The net profit attributable to shareholders was 315 million yuan, down 22.03% year-on-year - The net profit after deducting non-recurring items was 271 million yuan, a decline of 29.96% year-on-year - In Q2 2025, the company recorded a single-quarter main revenue of 382 million yuan, down 10.92% year-on-year, and a net profit of 185 million yuan, down 15.61% year-on-year [5][6]. Market Activity - On August 27, 2025, the stock had a trading volume of 59,800 lots and a transaction amount of 688 million yuan - Major funds had a net outflow of 63.02 million yuan, accounting for 9.16% of the total transaction amount, while retail investors had a net inflow of 56.06 million yuan, representing 8.15% of the total transaction amount [1][2]. Financing and Margin Trading - On August 27, 2025, the financing balance was 577 million yuan, with a net purchase of 28.30 million yuan - The margin trading balance stood at 579 million yuan, with a short selling volume of 0 shares and a remaining short selling amount of 17,200 shares [3][6]. Industry Comparison - Xinmai Medical's total market value is 13.818 billion yuan, compared to the industry average of 12.081 billion yuan, ranking 25th in the industry - The company has a net asset of 4.058 billion yuan, a net profit of 315 million yuan, and a price-to-earnings ratio of 21.96, significantly lower than the industry average of 73.16, ranking 12th in the industry [4][5].